The role of epigenetic mechanisms in cancer has gained interest in recent studies. The reversible nature of epigenetic changes on genomic DNA and histones holds promise for the development of ...

Fox Chase researchers use 3D genomic testing to improve lymphoma and sarcoma diagnosis and treatment by revealing tumor cell ...

It is well known that chronic inflammation can increase a person’s cancer risk, but the underlying mechanisms remain unknown. Now, a new study reveals, in a mouse model of colitis, gut tissues may ...

Cancer drugs known as BET inhibitors once looked like a breakthrough, but in real patients they’ve often fallen short. New ...

Chromatin is one of the earliest identified targets for cancer therapeutics. Drug development aimed at altering chromatin can be traced to the differentiating agents of the 1970s and their link to DNA ...

A person's lifetime risk for cancer may begin before they are even born, reports a paradigm-shifting study by Van Andel Institute scientists. If cancer does develop in the lower risk state, it is more ...

Using rapid protein degradation, chemogenomics, and super‑resolution microscopy in mouse embryonic stem cells, the team dissected the distinct contributions of BRD2 and BRD4 to transcription.

A new study from the Max Planck Institute of Immunobiology and Epigenetics in Freiburg offers a likely explanation for why ...

Zenith Epigenetic Ltd. ("Zenith" or the "Company") today held its annual general meeting of shareholders ("AGM"), during which President & CEO Donald McCaffrey provided an update to investors on ...